

Pirus Ghadjar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3710900/publications.pdf>

Version: 2024-02-01

159
papers

4,172
citations

109321

35
h-index

144013

57
g-index

163
all docs

163
docs citations

163
times ranked

5946
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	7.1	227
2	Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. <i>International Journal of Hyperthermia</i> , 2015, 31, 609-614.	2.5	173
3	Magnetic resonance thermometry: Methodology, pitfalls and practical solutions. <i>International Journal of Hyperthermia</i> , 2016, 32, 63-75.	2.5	173
4	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.6	157
5	The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. <i>International Journal of Cancer</i> , 2009, 125, 741-745.	5.1	127
6	Chemokine Receptor CCR6 Expression Level and Liver Metastases in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1910-1916.	1.6	126
7	Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. <i>BJU International</i> , 2014, 114, 360-367.	2.5	125
8	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 339-344.	0.8	122
9	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. <i>Journal of Clinical Oncology</i> , 2015, 33, 4158-4166.	1.6	99
10	Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2017, 12, 1.	2.7	87
11	Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. <i>International Journal of Hyperthermia</i> , 2017, 33, 471-482.	2.5	86
12	Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. <i>Brachytherapy</i> , 2009, 8, 45-51.	0.5	72
13	The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e583-e591.	0.8	67
14	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 80, 306-315.	1.9	64
15	Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. <i>Human Pathology</i> , 2008, 39, 1751-1755.	2.0	63
16	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 5-13.	0.6	62
17	Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94). <i>Radiation Oncology</i> , 2015, 10, 21.	2.7	58
18	Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. <i>World Journal of Gastroenterology</i> , 2016, 22, 833.	3.3	58

#	ARTICLE	IF	CITATIONS
19	Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) – Recommendations and Statements for Girls and Women. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 567-584.	1.8	56
20	CCL20/CCR6 expression profile in pancreatic cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 45.	4.4	53
21	Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 284-291.	0.8	53
22	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 904-910.	0.8	52
23	Quantitative Analysis of Extracapsular Extension of Metastatic Lymph Nodes and its Significance in Radiotherapy Planning in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1127-1132.	0.8	48
24	Non-thermal effects of radiofrequency electromagnetic fields. <i>Scientific Reports</i> , 2020, 10, 13488.	3.3	46
25	Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. <i>Radiation Oncology</i> , 2012, 7, 132.	2.7	45
26	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. <i>Insights Into Imaging</i> , 2016, 7, 205-214.	3.4	45
27	Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1181-1189.	2.5	44
28	High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1205-1212.	0.8	41
29	Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. <i>Radiation Oncology</i> , 2015, 10, 50.	2.7	40
30	Thermal magnetic resonance: physics considerations and electromagnetic field simulations up to 23.5 Tesla (1GHz). <i>Radiation Oncology</i> , 2015, 10, 201.	2.7	39
31	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. <i>European Urology</i> , 2013, 64, 931-938.	1.9	38
32	Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, 313-320.	0.4	37
33	Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 916-924.	0.8	37
34	Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer. <i>Radiation Oncology</i> , 2016, 11, 14.	2.7	37
35	MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 809-815.	3.3	36
36	The Relevance of Complementary and Integrative Medicine in the COVID-19 Pandemic: A Qualitative Review of the Literature. <i>Frontiers in Medicine</i> , 2020, 7, 587749.	2.6	36

#	ARTICLE	IF	CITATIONS
37	miR-21 functionally interacts with the 3'UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. <i>Cancer Letters</i> , 2012, 316, 105-112.	7.2	35
38	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 164.e1-164.e9.	1.6	35
39	Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 524-531.	0.8	34
40	miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: Significance of their regulation. <i>Oncology Reports</i> , 2013, 30, 1285-1292.	2.6	34
41	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. <i>Radiation Oncology</i> , 2017, 12, 140.	2.7	34
42	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. <i>Radiation Oncology</i> , 2018, 13, 90.	2.7	34
43	Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study. <i>Rare Tumors</i> , 2016, 8, 118-123.	0.6	31
44	CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. <i>Journal of Translational Medicine</i> , 2011, 9, 22.	4.4	30
45	Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. <i>Radiation Oncology</i> , 2019, 14, 160.	2.7	30
46	Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. <i>Radiation Oncology</i> , 2012, 7, 175.	2.7	29
47	Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. <i>BJU International</i> , 2015, 115, 571-579.	2.5	29
48	Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 122.	2.7	28
49	Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. <i>Radiation Oncology</i> , 2016, 11, 110.	2.7	28
50	Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. <i>Radiation Oncology</i> , 2008, 3, 35.	2.7	27
51	Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). <i>Radiotherapy and Oncology</i> , 2012, 104, 213-218.	0.6	26
52	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 619-626.	2.0	26
53	Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives. <i>Radiation Oncology</i> , 2016, 11, 65.	2.7	25
54	Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 700-706.	2.0	25

#	ARTICLE	IF	CITATIONS
55	Incidence of Small Lymph Node Metastases With Evidence of Extracapsular Extension: Clinical Implications in Patients With Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1366-1372.	0.8	24
56	Reducing radiation dose in the diagnosis of pulmonary embolism using adaptive statistical iterative reconstruction and lower tube potential in computed tomography. <i>European Radiology</i> , 2014, 24, 2685-2691.	4.5	24
57	Induction chemotherapy for unresectable urothelial carcinoma of the bladder. <i>BJU International</i> , 2011, 107, 894-897.	2.5	23
58	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 534-541.	0.8	23
59	Physical analysis of temperature-dependent effects of amplitude-modulated electromagnetic hyperthermia. <i>International Journal of Hyperthermia</i> , 2019, 36, 1245-1253.	2.5	23
60	Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 91, 237-242.	0.6	22
61	Ultrahypofractionation of localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 89-96.	2.0	22
62	High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 687-692.	2.0	21
63	Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies. <i>Tumor Biology</i> , 2011, 32, 189-196.	1.8	21
64	Unilateral and bilateral neck SIB for head and neck cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 232-239.	2.0	21
65	Prognostic Importance of Gleason 7 Disease Among Patients Treated With External Beam Radiation Therapy for Prostate Cancer: Results of a Detailed Biopsy Core Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1254-1261.	0.8	20
66	Non-thermal membrane effects of electromagnetic fields and therapeutic applications in oncology. <i>International Journal of Hyperthermia</i> , 2021, 38, 715-731.	2.5	20
67	Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells. <i>Journal of Translational Medicine</i> , 2014, 12, 48.	4.4	19
68	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. <i>Radiotherapy and Oncology</i> , 2018, 126, 257-262.	0.6	19
69	Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. <i>Radiation Oncology</i> , 2014, 9, 24.	2.7	17
70	Regional nodal relapse in surgically staged Merkel cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 51-58.	2.0	17
71	Radiofrequency applicator concepts for thermal magnetic resonance of brain tumors at 297 MHz (7.0 Tesla). <i>International Journal of Hyperthermia</i> , 2020, 37, 549-563.	2.5	17
72	Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer—a meta-analysis. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 1041-1049.	2.0	16

#	ARTICLE	IF	CITATIONS
73	Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment. <i>Cancers</i> , 2022, 14, 625.	3.7	16
74	Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland. <i>Laryngoscope</i> , 2013, 123, 662-669.	2.0	15
75	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. <i>PLoS ONE</i> , 2017, 12, e0186341.	2.5	15
76	Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. <i>Radiation Oncology</i> , 2015, 10, 244.	2.7	14
77	The oncologic role of local treatment in primary metastatic prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 755-761.	2.2	14
78	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	1.6	14
79	Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 17-24.	2.0	14
80	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 109-116.	2.0	14
81	Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems. <i>International Journal of Hyperthermia</i> , 2020, 37, 76-88.	2.5	14
82	Urethral toxicity vs. cancer control—Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. <i>Brachytherapy</i> , 2011, 10, 286-294.	0.5	13
83	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	2.0	13
84	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. <i>BJU International</i> , 2017, 120, E45-E51.	2.5	13
85	Radiofrequency applicator concepts for simultaneous MR imaging and hyperthermia treatment of glioblastoma multiforme. <i>Current Directions in Biomedical Engineering</i> , 2017, 3, 473-477.	0.4	13
86	Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. <i>Radiation Oncology</i> , 2018, 13, 251.	2.7	13
87	Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases. <i>World Journal of Gastroenterology</i> , 2011, 17, 3109-16.	3.3	13
88	Use of Gold Markers for Setup in Image-Guided Fractionated High-Dose-Rate Brachytherapy as a Monotherapy for Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 731-735.	2.0	12
89	Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis. <i>Radiation Oncology</i> , 2015, 10, 157.	2.7	12
90	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2016, 11, 48.	2.7	12

#	ARTICLE	IF	CITATIONS
91	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1025-1035.	0.8	12
92	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. <i>European Urology Focus</i> , 2015, 1, 173-184.	3.1	11
93	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapyâ€”Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , 2016, 2, 514-521.	3.1	11
94	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	2.0	11
95	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 589-597.	2.0	10
96	Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. <i>Radiation Oncology</i> , 2010, 5, 3.	2.7	9
97	Accelerated hyperfractionation plus temozolomide in glioblastoma. <i>Radiation Oncology</i> , 2016, 11, 70.	2.7	9
98	Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control. <i>Radiation Oncology</i> , 2018, 13, 64.	2.7	9
99	Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?. <i>Radiation Oncology</i> , 2018, 13, 3.	2.7	9
100	Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands. <i>International Journal of Cancer</i> , 2008, 123, 1565-1572.	5.1	8
101	Comparative analysis of prostateâ€”specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. <i>BJU International</i> , 2012, 110, E431-2; author reply E432.	2.5	8
102	Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. <i>Radiation Oncology</i> , 2015, 10, 138.	2.7	8
103	Definitive intensity modulated radiotherapy in locally advanced hypopharyngeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. <i>Radiation Oncology</i> , 2015, 10, 20.	2.7	8
104	Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1752-1761.	6.4	8
105	Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. <i>Radiation Oncology</i> , 2017, 12, 125.	2.7	7
106	Patient-Specific Planning for Thermal Magnetic Resonance of Glioblastoma Multiforme. <i>Cancers</i> , 2021, 13, 1867.	3.7	7
107	Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study. <i>Oral Oncology</i> , 2021, 116, 105240.	1.5	7
108	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. <i>Radiotherapy and Oncology</i> , 2021, 160, 140-147.	0.6	7

#	ARTICLE	IF	CITATIONS
109	Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions. Prostate Cancer, 2012, 2012, 1-8.	0.6	6
110	Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2018, 13, 113.	2.7	6
111	Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. Strahlentherapie Und Onkologie, 2020, 196, 229-242.	2.0	6
112	Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica, 2021, 62, 1200-1207.	1.1	6
113	Combined tumor plus nontumor interim FDGâ€PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. International Journal of Cancer, 2020, 147, 1427-1436.	5.1	6
114	Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis). Cancers, 2021, 13, 1133.	3.7	6
115	External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial. Radiation Oncology, 2021, 16, 76.	2.7	6
116	The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer. Deutsches Ärzteblatt International, 2019, 116, 849-856.	0.9	6
117	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21â€30. European Urology, 2016, 70, e11-e12.	1.9	5
118	Spinal cord constraints in the era of high-precision radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 561-569.	2.0	5
119	Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison. International Journal of Hyperthermia, 2018, 35, 314-322.	2.5	5
120	Radiotherapeutic treatment options for oligotopic malignant liver lesions. Radiation Oncology, 2021, 16, 51.	2.7	5
121	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
122	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. Archivos Espanoles De Urologia, 2015, 68, 296-306.	0.2	5
123	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443â€51. European Urology, 2012, 61, e39.	1.9	4
124	Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiation Oncology, 2008, 3, 22.	2.7	3
125	Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy. Frontiers in Oncology, 2016, 6, 48.	2.8	3
126	Re: Abdenour Nabid, Nathalie Carrier, AndrÃ©-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432â€31. European Urology, 2019, 75, e61-e62.	1.9	3

#	ARTICLE	IF	CITATIONS
127	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. <i>F1000Research</i> , 2020, 9, 1350.	1.6	3
128	Postoperative radiotherapy in prostate cancer. <i>Lancet, The</i> , 2021, 397, 1623.	13.7	3
129	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 993-1000.	2.0	3
130	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. <i>Cancer</i> , 2011, 117, 3532-3532.	4.1	2
131	Planning study for Merkel cell carcinoma based on the relapse pattern. <i>Radiotherapy and Oncology</i> , 2017, 123, 154-157.	0.6	2
132	A novel voxel based homogeneity index: Rationale and clinical implications for whole-brain radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 229-235.	0.6	2
133	Optimizing radiotherapy for intermediate-risk localized disease. <i>Nature Reviews Urology</i> , 2018, 15, 470-471.	3.8	2
134	Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. <i>Lancet Oncology, The</i> , 2020, 21, e11.	10.7	2
135	Improved patient-specific hyperthermia planning based on parametrized electromagnetic and thermal models for the SIGMA-30 applicator. <i>International Journal of Hyperthermia</i> , 2021, 38, 663-678.	2.5	2
136	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5038-5038.	1.6	2
137	Experimental and computational evaluation of capacitive hyperthermia. <i>International Journal of Hyperthermia</i> , 2022, 39, 504-516.	2.5	2
138	Randomized Pilot Trial Using External Yarrow Liver Compress Applications With Metastatic Cancer Patients Suffering From Fatigue: Evaluation of Sympathetic Modulation by Heart Rate Variability Analysis. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542210812.	2.0	2
139	Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation. <i>Cancers</i> , 2022, 14, 2418.	3.7	2
140	Letter to the Editor on: A. Siegmann et al. Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical ProgressionFree Survival. Results of a Retrospective Study. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 763-764.	2.0	1
141	Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). <i>Oral Oncology</i> , 2013, 49, 1006-1009.	1.5	1
142	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 28.	2.2	1
143	In Regard to Pisansky etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 438-439.	0.8	1
144	Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1490-1491.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>Eur Urol</i> 2017;72:910â€“7. <i>European Urology</i> , 2018, 73, e34-e35.	1.9	1
146	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>Eur Urol</i> 2019;76:732â€“9. <i>European Urology</i> , 2020, 77, e60-e61.	1.9	1
147	In Regard to Wang etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 855.	0.8	1
148	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1746-1746.	1.6	1
149	Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial. <i>European Urology</i> , 2021, 80, 117.	1.9	1
150	In Response to Dr. Lacout etÂal.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 962.	0.8	0
151	RE: Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt464-djt464.	6.3	0
152	Reply to C. Cozzarini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1705-1706.	1.6	0
153	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 319.	1.9	0
154	Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>Eur Urol</i> 2018;73:156â€“65. <i>European Urology</i> , 2018, 73, e63.	1.9	0
155	In Regard to Qi etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 224-225.	0.8	0
156	Mode of Action and Experimental and Clinical Data of Regional Hyperthermia. , 2021, , 141-149.		0
157	Hyperthermie in Kombination mit Radiotherapie in der Tumorbehandlung. <i>Springer Reference Medizin</i> , 2021, , 1-10.	0.0	0
158	Chemotherapy with irradiation in salivary gland carcinomas (SGC): A Rare Cancer Network study (RCN).. <i>Journal of Clinical Oncology</i> , 2013, 31, e17019-e17019.	1.6	0
159	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 260-260.	1.6	0